Rib-X℠ is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. More

02.07.12 - Rib-X Pharmaceuticals Receives $3 Million Milestone Payment from Sanofi in the RX-04 Collaboration  Read More 

12.15.11 - Rib-X Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections Read More 

11.28.11 - Rib-X Pharmaceuticals Files Registration Statement For Proposed Initial Public Offering Read More